Evaluating a Prognostic Tool for Metastatic Breast Cancer
This study is looking at a tool designed to help doctors, nurse practitioners, physician assistants, and nurse navigators identify patients with metastatic breast cancer (cancer that has spread to other parts of the body) who might be at high risk of dying within 30 days. Researchers will interview these healthcare professionals to understand how acceptable, appropriate, and easy-to-use this tool is in their daily practice. The goal is to find out what helps or hinders them from using such a tool. This information will help create a plan for successfully using this tool in the future to improve end-of-life care for patients. This is an observational study, meaning no new treatments are being given. The study aims to interview about 10-15 clinicians.
- Study design
- This is an observational study involving qualitative interviews with healthcare professionals. It plans to include about 10-15 participants.
- What's involved
- If you are a healthcare professional, you would participate in a qualitative interview over the phone or secure video conferencing.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes, such as barriers and facilitators for using the prognostic tool, will be measured at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Emily Ray, MD · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Key barriers for use a metastatic breast cancer-specific prognostic tool12 months
Study Investigators have developed a metastatic breast cancer (MBC)-specific prognostic calculator using the ASCO CancerLinQ Discovery database to help oncologists better estimate prognosis in MBC patients. Key barriers using this metastatic breast cancer-specific prognostic tool will be identified, through semi-structured qualitative interviews with oncology clinicians.
- Key facilitators for use of a metastatic breast cancer-specific prognostic tool12 months
Study Investigators have developed a metastatic breast cancer (MBC)-specific prognostic calculator using the ASCO CancerLinQ Discovery database to help oncologists better estimate prognosis in MBC patients. Key facilitators using this metastatic breast cancer-specific prognostic tool will be identified, through semi-structured qualitative interviews with oncology clinicians.